Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Announces 2014 Development Road Map

1303

Dallas, Texas 01/31/2014 (FINANCIALSTRENDS) – On 13th January, the $327 million market capped, development stage drug maker Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported updates on its pipeline of target compounds that it has been developing to treat chronic hepatitis C (HCV).

Dr. Milind Deshpande, President and Chief Executive Officer of Achillion has been quoted to have said that, ” With the emerging safety and in vitro data on ACH-3422, a uridine nucleotide inhibitor of NS5B polymerase, and the 12-week clinical activity reported with ACH-3102, our Phase 2, pan-genotypic, second-generation NS5A inhibitor, we believe that our HCV compounds are well-positioned to achieve positive results in the clinical studies we plan to initiate throughout 2014. We believe we have sufficient capital to fund our operations into 2016 and achieve a number of value-creating milestones throughout this year with our HCV assets.”

The development stage drug firm boasted of cash reserves of close to $150 million at the end of 2013, which it has indicated would broadly support the development of commercially viable therapies designed to alleviate the suffering of patients with chronic hepatitis C by administering their short duration treatments.

With respect to the 2014 Milestones, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported the following roadmaps. For its target drug “ACH-3422: HCV Nucleotide NS5B Polymerase Inhibitor” the drug maker wants to progress its current pre-clinical trials into clinical tests with the phase 1 of these trials slated to being in mid 2014 and hopes to report initial results by third quarter of this year.

On its other lead drug candidate” ACH-3102 + sofosbuvir”, the drug maker has reported that it plans to kick start its phase 2 pilot study in the April to June’ 14 time frame and has planned a 8 week test period in which the chronic hepatitis C patients will be administered this test drug.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.